Showing 1341-1350 of 1614 results for "".
- Belite Bio’s Tinlarebant Studied to Treat Childhood-onset Stargardt Diseasehttps://modernod.com/news/belite-bios-tinlarebant-studied-to-treat-childhood-onset-stargardt-disease/2481950/Belite Bio presented final data from a 24-month, phase 2 study of Tinlarebant (LBS-008) in adolescent Stargardt disease (STGD1). The study—LBS-008-CT02—enrolled 12 adolescent STGD1 patients, aged 12-18 years, who completed
- FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platformhttps://modernod.com/news/fda-grants-breakthrough-device-status-to-tokus-patented-cardiovascular-risk-ai-clair-platform/2481934/Toku announced that the FDA has granted Breakthrough Device designation to its patented CLAiR technology. According to Toku, the CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive
- Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopiahttps://modernod.com/news/alcon-launches-total30-multifocal-contact-lenses-for-patients-with-presbyopia/2481879/Alcon announced the global launch of TOTAL30 Multifocal, the first and only monthly water gradient multifocal contact lens, according to Alcon. The lenses have begun to roll out in the United States and in select international markets. Many lens wearers stop wearing contact le
- Neurolens Introduces N3 VR-Based Measurement and Education Experiencehttps://modernod.com/news/neurolens-introduces-n3-vr-based-measurement-and-education-experience/2481854/Neurolens has introduced N3—a virtual reality experience designed to educate patients while measuring eye alignment. N3 provides an objective, accurate, and repeatable measurement of binocular alignment, which incorporates elements of heterophoria, fixation disparit
- Thea Pharma Announces the US Launch of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-the-us-launch-of-glaucoma-drug-iyuzeh/2481850/Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (
- Eye Care Charity Orbis Announces New Partnership with Heidelberg Engineeringhttps://modernod.com/news/eye-care-charity-orbis-announces-new-partnership-with-heidelberg-engineering/2481817/Orbis announced a new partnership with Heidelberg Engineering in which Heidelburg will fund crucial teaching opportunities and research—focusing on training eye care professionals around the world via Cybersight (Orbis’s telemedicine and e-learning p
- Rayner Completes First Implantations of IOLs in Clinical Trials in China and the UShttps://modernod.com/news/rayner-achieves-milestone-implantations-in-clinical-trials-in-china-and-the-us/2481774/Rayner has announced the completion of the first implantations in two pivotal market access studies in the US and China. Rayner's RayOne EMV Toric IOL received investigational device exemption (IDE) approval from the FDA in June. The first study implantation took place at
- Lars Ederleh Named New CSO at Schwind Eye-Tech-Solutionshttps://modernod.com/news/lars-ederleh-named-new-cso-at-schwind-eye-tech-solutions/2481731/Schwind eye-tech-solutions has named Lars Ederleh as Chief Sales Officer (CSO), effective this month. Bringing more than 20 years of international experience in laser technology, Mr. Ederleh will be in charge of the company’s sales and marketing operations.
- Dean Burns Named President and CEO of Ocumeticshttps://modernod.com/news/dean-burns-named-president-and-ceo-of-ocumetics/2481722/Ocumetics Technology has appointed ophthalmic executive Dean Burns as President and CEO. Mr. Burns, whoj will also join the Ocumetics board of directors, was previously a consultant for Ocumetics, assisting with regulatory and marketing endeavours. Mr. Burns replaces 
- Nicox Estimates Potential Annual Global Net Sales for NCX 470 of Over $300 Millionhttps://modernod.com/news/nicox-estimates-potential-annual-global-net-sales-for-ncx-470-of-over-300-million/2481712/Nicox SA said it that annual global net sales of NCX 470 could be over $300 million within 8 years of the date of launches in the U.S. and China. The estimate was based on a US market survey evaluating the commercial potential of NCX 470, a nitric oxide (NO)-donating bima